drugset / Trial / NCT06353360
TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is To investigate the safety and efficacy of Tumor-Treating Fields (TTFields) in combined with temozolomide (TMZ) and tislelizumab in the treatment of newly diagnosed glioblastoma (GBM).
Timeline
- Start
- 2024-04-30
- Primary completion
- 2025-07-15
- Completion
- 2026-03-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temozolomide | Small molecule | 200 mg/m2 | — |
| Subject | Tislelizumab | Monoclonal antibody | 300 mg | Intravenous |